Ibutilide: A class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter

Journal of Emergency Medicine

Volumn 20, Issue 1, 2001, Pages 67-71

  Rogers, Kelly C ^a   Wolfe, Douglas A ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Antidysrhythmic agents; Atrial fibrillation; Atrial flutter

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; IBUTILIDE;

ARTICLE; CARDIOVERSION; DRUG EFFICACY; DRUG INDICATION; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; NAUSEA; PATIENT SELECTION; PRIORITY JOURNAL; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; HUMANS; INJECTIONS, INTRAVENOUS; PATIENT SELECTION; SULFONAMIDES; TIME FACTORS;

EID: 0035140625     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-4679(00)00274-2     Document Type: Article

References (26)

1. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter; a dose-response study
2. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation
3. Efficacy of ibutilide for termination of atrial fibrillation and flutter
4. Atrial fibrillation and atrial flutter
5. Introduction; acute treatment of atrial fibrillation and flutter-ibutilide in perspective
6. Management of atrial fibrillation
7. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association
8. Mortality and morbidity in patients receiving encainide, flecainide, or placebo; the Cardiac Arrhythmia Suppression Trial
9. The Cardiac Arrhythmia Suppression Trial; first CAST then CAST-II
10. Ibutilide; a new class III antiarrhythmic agent
11. Electrophysiology and pharmacology of ibutilide
12. + current in guinea pig ventricular cells
13. kr) in AT-1 cells; concentration-, voltage-, and use-dependent effects
14. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function
15. An analysis of the time relations of electrocardiography
16. Efficacy and safety of repeated intravenous doses of ibutilide for the rapid conversion of atrial flutter or fibrillation
17. Effects of ibutilide fumarate, a new class III antiarrhythmic agent
18. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter
19. Proven efficacy of repeated dose intravenous ibutilide, a class III antiarrhythmic drug, for rapid termination of chronic atrial flutter or fibrillation; results of a multicenter placebo-controlled study
20. Management of patients with atrial fibrillation
21. Antithrombotic therapy in atrial fibrillation
22. Ibutilide is safe for conversion of atrial fibrillation in patients on concomitant antiarrhythmic agents
23. Catheter ablation of atrial flutter and fibrillation
24. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter and fibrillation